BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12358061)

  • 21. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine.
    Kristiansen PA; Diomandé F; Wei SC; Ouédraogo R; Sangaré L; Sanou I; Kandolo D; Kaboré P; Clark TA; Ouédraogo AS; Absatou KB; Ouédraogo CD; Hassan-King M; Thomas JD; Hatcher C; Djingarey M; Messonnier N; Préziosi MP; LaForce M; Caugant DA
    Clin Vaccine Immunol; 2011 Mar; 18(3):435-43. PubMed ID: 21228139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal group B vaccines.
    Findlow J
    Hum Vaccin Immunother; 2013 Jun; 9(6):1387-8. PubMed ID: 23732894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
    Carr JP; MacLennan JM; Plested E; Bratcher HB; Harrison OB; Aley PK; Bray JE; Camara S; Rodrigues CMC; Davis K; Bartolf A; Baxter D; Cameron JC; Cunningham R; Faust SN; Fidler K; Gowda R; Heath PT; Hughes S; Khajuria S; Orr D; Raman M; Smith A; Turner DPJ; Whittaker E; Williams CJ; Zipitis CS; Pollard AJ; Oliver J; Morales-Aza B; Lekshmi A; Clark SA; Borrow R; Christensen H; Trotter C; Finn A; Maiden MC; Snape MD;
    Clin Microbiol Infect; 2022 Dec; 28(12):1649.e1-1649.e8. PubMed ID: 35840033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
    Findlow H; Borrow R
    Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine.
    Bårnes GK; Kristiansen PA; Beyene D; Workalemahu B; Fissiha P; Merdekios B; Bohlin J; Préziosi MP; Aseffa A; Caugant DA
    BMC Infect Dis; 2016 Nov; 16(1):639. PubMed ID: 27814682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.
    MacNeil JR; Blain AE; Wang X; Cohn AC
    Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
    Trotter CL; Edmunds WJ; Ramsay ME; Miller E
    Hum Vaccin; 2006; 2(2):68-73. PubMed ID: 17012888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines.
    Diggle MA; Clarke SC
    J Clin Microbiol; 2005 Sep; 43(9):4649-53. PubMed ID: 16145121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.
    MacLennan JM; Rodrigues CMC; Bratcher HB; Lekshmi A; Finn A; Oliver J; Wootton M; Ray S; Cameron C; Smith A; Heath PT; Bartolf A; Nolan T; Hughes S; Varghese A; Snape MD; Sewell R; Cunningham R; Stolton A; Kay C; Palmer K; Baxter D; Suggitt D; Zipitis CS; Pemberton N; Jolley KA; Bray JE; Harrison OB; Ladhani SN; Pollard AJ; Borrow R; Gray SJ; Trotter C; Maiden MCJ
    Lancet Infect Dis; 2021 May; 21(5):677-687. PubMed ID: 33482143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
    Trotter CL; Ramsay ME; Kaczmarski EB
    Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
    Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
    Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces.
    Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J
    Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.